Use of combination therapy to successfully treat breakthrough Trichosporon asahii infection in an acute leukemia patient receiving voriconazole

Jia Chen; Feng Chen; Ying Wang; Ling-Yi Yang; Miao Miao; Yue Han; De-Pei Wu

doi:10.1016/j.mmcr.2014.09.003

Use of combination therapy to successfully treat breakthrough Trichosporon asahii infection in an acute leukemia patient receiving voriconazole

Med Mycol Case Rep. 2014 Oct 19:6:55-7. doi: 10.1016/j.mmcr.2014.09.003. eCollection 2014 Oct.

Authors

Jia Chen¹, Feng Chen¹, Ying Wang¹, Ling-Yi Yang², Miao Miao¹, Yue Han¹, De-Pei Wu¹

Affiliations

¹ Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China ; Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, China.
² Respiratory Department, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Abstract

Trichosporon species is an important life-threatening opportunistic systemic pathogen, especially in leukemia patients. Voriconazole is proved to be a promising agent in past decade. However, recently we observed a case of breakthrough Trichosporon asahii infection while receiving voriconazole, which calls for an alternative treatment strategy. A combination therapy of liposomal amphotericin B (AmB) plus caspofungin - in which liposomal AmB dose was reduced due to renal toxicity - was administered to successfully treat this patient.

Keywords: Caspofungin; Liposomal amphotericin B; T. asahii; Voriconazole.